Multidrug resistance markers P-glycoprotein, multidrug resistance protein 1, and lung resistance protein in non-small cell lung cancer: prognostic implications
- 27 January 2005
- journal article
- research article
- Published by Springer Nature in Zeitschrift für Krebsforschung und Klinische Onkologie
- Vol. 131 (6) , 355-363
- https://doi.org/10.1007/s00432-004-0653-9
Abstract
The aim of this retrospective study was to comparatively investigate the expression of the three drug-resistance genes P-glycoprotein (P-gp), multidrug-resistance protein 1 (MRP1), and lung resistance protein (LRP), in non-small cell lung cancer (NSCLC) tissues, and to assess possible associations with clinicopathologic features.Keywords
This publication has 33 references indexed in Scilit:
- Predicting Chemotherapy Response to Paclitaxel-Based Therapy in Advanced Non-Small-Cell Lung Cancer with P-Glycoprotein ExpressionRespiration, 2003
- Multidrug resistance in cancer: role of ATP–dependent transportersNature Reviews Cancer, 2002
- Vaults Are Up-regulated in Multidrug-resistant Cancer Cell LinesJournal of Biological Chemistry, 1998
- MRP is frequently expressed in human lung-cancer cell lines, in non-small-cell lung cancer and in normal lungInternational Journal of Cancer, 1996
- Expression of the multidrug resistance-associated protein (MRP) gene in primary non-small-cell lung cancerAnnals of Oncology, 1996
- Preferential expression of the multidurg‐resistance‐associated protein (MRP) in adenocarcinoma of the lungInternational Journal of Cancer, 1995
- Expression of the multidrug resistance-associated protein (MRP) gene in human lung tumours and normal tissue as determined by in situ hybridisationEuropean Journal Of Cancer, 1994
- Expression of the Multidrug Resistance Gene (MDR1) in Non‐small Cell Lung CancerJapanese Journal of Cancer Research, 1994
- Multidrug Resistance-Associated Protein: Sequence CorrectionScience, 1993
- Non-small cell lung cancer Part II: TreatmentCurrent Problems in Cancer, 1991